Drug intelligence / Profile preview

Artynodol

Development stage: Unknown
Lead developer: Jointherapeutics
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**Artynodol** is a JoinTherapeutics nutraceutical food supplement formulated with *Commiphora myrrha* extract, glucosamine, chondroitin, bromelain, and turmeric extract. It is intended to support chondroprotection in osteoarthritis and has been launched in Italy, with a forthcoming launch stated for the United Arab Emirates. ([jointherapeutics.com](https://www.jointherapeutics.com/products/))

Brand names: Artynodol

Beyond the preview

Go deeper on Artynodol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artynodol.

Explore the full profile